|
|
Substance Name: Pravastatin sodium [USAN:USP:JAN]
RN: 81131-70-6
UNII: 3M8608UQ61
InChIKey: VWBQYTRBTXKKOG-IYNICTALSA-M
Note
- An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).
Molecular Formula
- C23-H35-Na-O7
Molecular Weight
- 446.5125
- All
- Classifications
- Links to Resources
- Names & Synonyms
- Registry Numbers
- Structure Descriptors
- Toxicity
- Physical Properties
Classification Codes
- Antihyperlipidemic
- Drug / Therapeutic Agent
- Human Data
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Regulatory Agencies (Superlist Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Pravastatin sodium [USAN:USP:JAN]
Synonyms
- 3-beta-Hydroxycompactin sodium salt
- Aplactin
- Bristacol
- CS-514
- DRG-0319
- Elisor
- Epastatin sodium
- Lipemol
- Lipidal
- Lipostat
- Liprevil
- Mevalotin
- Pralidon
- Prareduct
- Pravachol
- Pravacol
- Pravaselect
- Pravasin
- Pravasine
- Pravastatin Natrium Mayrho Fer
- Pravastatin sodium
- Sanaprav
- Selektine
- Selipran
- Sodium (+)-(betaR,deltaR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-hexahydro-beta,delta,6,8-tetrahydroxy-2-methyl-1-naphthaleneheptanoate, 8-((2S)-2-methylbutyrate)
- SQ 31000
- SQ-31,000
- UNII-3M8608UQ61
- Vasen
Systematic Names
- 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-2-methyl-8-(2-methyl-1-oxobutoxy)-beta,delta,6-trihydroxy-, monosodium salt, (1S-(1-alpha(beta-S*,delta-S*),2-alpha,6-alpha,8-beta(R*),8a-alpha))-
- 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-
Superlist Name
- Pravastatin sodium
Mixture Name
- Pravigard PAC
Registry Numbers
CAS Registry Number
- 81131-70-6
FDA UNII
- 3M8608UQ61
Other Registry Numbers
- 115873-26-2
- 81131-73-9
- 85956-24-7
- 87098-76-8
Related Registry Number
- 81093-37-0 (Parent)
System Generated Number
- 0081131706
Structure Descriptors
InChI
InChI=1S/C23H36O7.Na/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28;/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28);/q;+1/p-1/t13-,14-,16+,17+,18+,19-,20-,22-;/m0./s1InChIKey
VWBQYTRBTXKKOG-IYNICTALSA-MSmiles
[Na+].CC[C@H](C)Toxicity
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
man | TDLo | oral | 16mg/kg/8W-I (16mg/kg) | LIVER: "JAUNDICE, CHOLESTATIC" LIVER: LIVER FUNCTION TESTS IMPAIRED SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | American Journal of Emergency Medicine. Vol. 17, Pg. 1388, 1999. |
mouse | LD50 | intravenous | 2011mg/kg (2011mg/kg) | LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987. |
mouse | LD50 | oral | 8939mg/kg (8939mg/kg) | GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE BLOOD: CHANGES IN SPLEEN | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987. |
mouse | LD50 | subcutaneous | 2975mg/kg (2975mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987. |
rat | LD50 | intravenous | 440mg/kg (440mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987. |
rat | LD50 | oral | > 12gm/kg (12000mg/kg) | Yakkyoku. Pharmacy. Vol. 40, Pg. 2351, 1989. | |
rat | LD50 | subcutaneous | 3172mg/kg (3172mg/kg) | LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BEHAVIORAL: ATAXIA SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987. |
rat | LDLo | intraperitoneal | 400mg/kg (400mg/kg) | Biochemistry and Molecular Biology International. Vol. 47, Pg. 519, 1999. | |
women | TDLo | oral | 16800ug/kg (16.8mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Lancet. Vol. 340, Pg. 910, 1992. |
women | TDLo | oral | 30mg/kg/21W-I (30mg/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" BLOOD: "CHANGES IN SERUM COMPOSITION (E.G., TP, BILIRUBIN, CHOLESTEROL)" BEHAVIORAL: MUSCLE WEAKNESS | New England Journal of Medicine. Vol. 327, Pg. 649, 1992. |
Physical Properties
Physical Property | Value | Units | Temp (deg C) | Source |
---|---|---|---|---|
log P (octanol-water) | -0.23 | (none) | EXP | |
Water Solubility | 2460 | mg/L | 25 | EST |
Vapor Pressure | 3.60E-23 | mm Hg | 25 | EST |
Atmospheric OH Rate Constant | 2.41E-10 | cm3/molecule-sec | 25 | EST |
Physical property data is provided to ChemIDplus by SRC, Inc.